Viela Bio collaborates with Hansoh Pharma to develop and commercialize inebilizumab for autoimmune diseases and hematologic cancers in China

This article was originally published here

“Our collaboration with Hansoh Pharma strengthens our ability to commercialize inebilizumab throughout the world,” commented Bing Yao, Ph.D., Viela’s Executive Chairman and Chief Executive Officer. “Their significant commercial,

The post Viela Bio collaborates with Hansoh Pharma to develop and commercialize inebilizumab for autoimmune diseases and hematologic cancers in China appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply